Innate Pharma Files 6-K Report

Ticker: IPHYF · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type6-K
Filed DateSep 15, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: foreign-private-issuer, sec-filing, press-release

Related Tickers: IPHA

TL;DR

Innate Pharma (IPHA) filed a 6-K on 9/15/25 with a press release attached.

AI Summary

Innate Pharma SA filed a Form 6-K on September 15, 2025, reporting a press release dated September 15, 2025. The filing is for a foreign private issuer and indicates that the company files annual reports under Form 20-F. The principal executive office is located in Marseille, France.

Why It Matters

This filing provides an update from Innate Pharma SA, a French biotechnology company, to the SEC, which may contain important information for investors regarding its operations or recent developments.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not appear to contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

  • Innate Pharma SA (company) — Registrant
  • September 15, 2025 (date) — Filing Date
  • 117 Avenue de Luminy—BP 30191 13009 Marseille, France (address) — Principal Executive Office
  • Form 6-K (document) — Filing Type
  • Form 20-F (document) — Annual Report Filing

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

What is the filing date of this Form 6-K?

The filing date of this Form 6-K is September 15, 2025.

Where is Innate Pharma SA's principal executive office located?

Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.

Does Innate Pharma SA file annual reports under Form 20-F?

Yes, the filing indicates that Innate Pharma SA files annual reports under Form 20-F.

What exhibit is included with this Form 6-K?

Exhibit 99.1, a Press Release dated September 15, 2025, is included with this Form 6-K.

Filing Stats: 159 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-09-15 06:00:44

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 15, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.